Energenesis Biomedical partners with Taiwan Tanabe Seiyaku to develop topical drug for diabetic foot ulcers

Energenesis Biomedical has entered into a joint development agreement with Taiwan Tanabe Seiyaku, the wholly owned ...

August 7, 2026 | Friday | News
Korea's Alteogen inks $365 M deal for development and commercialisation of Hybrozyme™-enabled subcutaneous biologic product

Alteogen Inc., a South Korea-based biopharmaceutical company specialising in platform technologies, has entered into an ...

August 6, 2026 | Thursday | News
FDA approves Moderna’s mRNA seasonal influenza vaccine

The US Food and Drug Administration has approved Moderna’s mFlusiva seasonal influenza vaccine for adults aged 50 ...

August 6, 2026 | Thursday | News
Zuellig Pharma’s John Graham on strengthening medicine authenticity across Asia

Counterfeit and unauthorised healthcare products remain a persistent risk across Asia, particularly where fragmented dis...

August 5, 2026 | Wednesday | Opinion
Antengene receives $60 million upfront payment under UCB autoimmune therapy deal

Antengene has received a $60 million upfront payment from UCB under a worldwide exclusive licensing agreement for ATG-20...

August 3, 2026 | Monday | News
Kelun-Biotech receives China clearance to begin clinical development of dual-payload ADC

Kelun-Biotech has received approval from the Center for Drug Evaluation of China’s National Medical Products Admin...

August 3, 2026 | Monday | News
“Thailand’s competitive strength lies in its ability to consistently deliver high-quality clinical trials at scale”

How would you assess the current state of Thailand's life sciences ecosystem, and what key developments have stood out o...

August 1, 2026 | Saturday | Opinion
The Third Dimension of Antibody Therapy

Bispecific antibodies have transformed treatment by simultaneously targeting two molecules, delivering significant clini...

August 1, 2026 | Saturday | Analysis
Bridging the Rare Disease Access Gap in Asia-Pacific

Although each rare disease affects only a small number of people, collectively they represent one of the world's largest...

August 1, 2026 | Saturday | Analysis
Ember LifeSciences and Alfresa Corp to improve quality of pharmaceutical cold chain in Japan

Ember LifeSciences, Inc. has entered into a capital and business alliance with Alfresa Corporation, a subsidiary of Alfr...

August 1, 2026 | Saturday | News
AbbVie announces availability of ELAHERE® in Singapore for treatment of platinum-resistant ovarian cancer

AbbVie has announced the availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the treatment of plat...

July 30, 2026 | Thursday | News
Ono Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientist

Japan-based Ono Pharmaceutical and US-based Phylo, Inc. have announced a collaboration that brings Biomni Lab, Phylo's a...

July 30, 2026 | Thursday | News
DKSH Korea expands strategic partnership with Novartis for hypertension treatment

DKSH Business Unit Healthcare, a strategic healthcare solutions partner and leading provider of Market Expansion Service...

July 30, 2026 | Thursday | News
Single-Use Bioreactors Are Redefining Asia's Next Generation of Biomanufacturing

Asia's biopharmaceutical manufacturing sector is entering a new phase of growth, driven by expanding biologics pipelines...

July 29, 2026 | Wednesday | Influencers
Nippon Kayaku and Celltrion Healthcare Japan join hands for stable supply of biopharmaceuticals

Nippon Kayaku and Celltrion Healthcare Japan K.K. have entered into a Memorandum of Understanding (MoU) on Compreh...

July 29, 2026 | Wednesday | News
China approves Takeda’s ORZEYFUL (oveporexton) as first Orexin Agonist and only medicine to treat Narcolepsy Type 1

Takeda China has announced that the National Medical Products Administration (NMPA) has approved the use of ORZEYFUL (ov...

July 27, 2026 | Monday | News
Why Europe, not America, may be Chinese sponsors’ smartest move

It is estimated that by 2040 China-originated treatments will represent 35% of US FDA approvals. When marketing treatmen...

July 24, 2026 | Friday | Opinion
Korea's GCCL and GemPharmatech sign MoU to advance global drug discovery and development services

GCCL, a South Korea-based leading provider of clinical trial sample analysis, and China & US based GemPharmatech, a ...

July 24, 2026 | Friday | News
Gerresheimer starts operations at new plant in China for pharma packaging

Gerresheimer, an innovative system and solution provider and global partner to the pharma, biotech, and cosmetic industr...

July 24, 2026 | Friday | News
Devonian receives Health Canada authorisation for paediatric Thykamine trial

Devonian Health Group has received Health Canada authorisation to initiate a Phase II/III paediatric clinical trial of P...

July 23, 2026 | Thursday | News
Novartis to invest KRW 140 B in Korea’s radioligand therapy ecosystem

The Ministry of Health and Welfare (MoHW), South Korea, and Novartis have signed a Memorandum of Understanding (MoU) und...

July 23, 2026 | Thursday | News
ING podcast examines China’s biotech rise and shifting global pharma order

ING has examined the shifting global pharmaceutical landscape in a podcast discussion focused on China’s biotech b...

July 22, 2026 | Wednesday | News
Monash University signs MoU with Therapeutic Goods Administration for pharma regulatory science

Monash University has signed a Memorandum of Understanding (MoU) with Australia’s Therapeutic Goods Administration...

July 22, 2026 | Wednesday | News
Japan's JCR Pharma receives marketing authorisation in UAE for IZCARGO to treat Hunter Syndrome

JCR Pharmaceuticals Co., a global specialty biopharmaceutical company dedicated to developing therapies for rare and gen...

July 22, 2026 | Wednesday | News
Halozyme, Incyte partner on subcutaneous formulation of mutCALR antibody

Halozyme Therapeutics has entered a global collaboration and licence agreement with Incyte to evaluate additional subcut...

July 21, 2026 | Tuesday | News